Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis, Systemic 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hypereosinophilic Syndrome 1Chondrosarcoma 1

Interventions

nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mastocytosis, Systemic × nilotinib × Clear all
NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Novartis

Phase 1/2 Completed
507 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡